Share Price and Basic Stock Data
Last Updated: December 4, 2025, 2:27 am
| PEG Ratio | 1.20 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Chandra Bhagat Pharma Ltd, operating within the pharmaceuticals sector, reported a significant increase in revenue trends over the years. The company’s sales rose from ₹48.01 Cr in Mar 2014 to ₹119.67 Cr in Mar 2023, showcasing a compound annual growth rate (CAGR) of approximately 10.71%. However, the latest reported figure for Mar 2025 indicated a decline to ₹86.72 Cr, reflecting challenges in sustaining growth post a peak in Mar 2024 when sales reached ₹221.37 Cr. The quarterly performance further illustrates this trend, with sales peaking at ₹119.26 Cr in Sep 2023 but subsequently dropping to ₹21.80 Cr in Mar 2025. This volatility in revenue suggests potential market fluctuations or operational challenges affecting performance. The overall growth trajectory from a historical perspective indicates a capacity for expansion, though recent results raise concerns about maintaining momentum in a competitive market.
Profitability and Efficiency Metrics
The profitability measures for Chandra Bhagat Pharma Ltd present a mixed picture. The company’s operating profit margin (OPM) stood at -1.19%, indicating operational inefficiencies compared to industry peers, which typically hover around 10-15%. The net profit for Mar 2025 was reported at ₹0.86 Cr, with a net profit margin of 0.98%, highlighting a struggle to convert revenue into profit effectively. The interest coverage ratio (ICR) of 2.09x suggests that the company can cover its interest obligations, albeit with limited buffer. Additionally, return on equity (ROE) was reported at 2.41%, and return on capital employed (ROCE) at 6.00%, both of which are below average for the sector, indicating suboptimal use of equity and capital. The company’s ability to improve these metrics will be crucial in restoring investor confidence and ensuring long-term viability.
Balance Sheet Strength and Financial Ratios
Chandra Bhagat Pharma’s balance sheet reflects a challenging financial position, with total borrowings reported at ₹21.11 Cr against reserves of ₹22.87 Cr, indicating a thin margin of safety. The debt-to-equity ratio stands at 0.69, which is relatively high and suggests a reliance on debt financing, posing risks in adverse market conditions. The current ratio of 1.41 and quick ratio of 1.40 indicate adequate liquidity to meet short-term obligations. However, the company’s working capital days have increased to 115.28 days, highlighting potential inefficiencies in inventory management and receivables collection. This extended cash conversion cycle could strain liquidity and operational efficiency. Furthermore, the book value per share increased to ₹39.72, reflecting a solid equity base, yet the price-to-book value (P/BV) ratio of 1.32x indicates that the stock may not be undervalued compared to its book value.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Chandra Bhagat Pharma Ltd indicates a strong promoter holding of 72.19%, which may suggest confidence from the management in the company’s future prospects. Foreign institutional investors (FIIs) hold a minor stake of 0.61%, while domestic institutional investors (DIIs) have no reported holdings, reflecting limited institutional interest. The public shareholding stands at 27.20%, which has fluctuated over time, indicating varying levels of retail investor confidence. The total number of shareholders has seen an increase to 301, which could be interpreted as a positive sign of growing interest among retail investors. However, the lack of significant institutional investment raises concerns regarding the company’s perceived stability and growth potential, as institutional backing is often viewed as a vote of confidence in a company’s strategic direction and governance.
Outlook, Risks, and Final Insight
The outlook for Chandra Bhagat Pharma Ltd hinges on its ability to stabilize revenues and improve profitability metrics. The company faces risks from declining sales post-peak, operational inefficiencies reflected in negative profit margins, and a high debt burden that could hinder growth. Additionally, the company’s reliance on promoter support without substantial institutional backing may limit its ability to attract further investment. The potential for operational restructuring, improved inventory management, and strategic market positioning could offer pathways to recovery. If the company successfully addresses these challenges, it may regain momentum and enhance shareholder value. Conversely, failure to adapt could result in continued volatility and diminished investor confidence. Maintaining a close watch on quarterly performance and market conditions will be essential for stakeholders.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Chandra Bhagat Pharma Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 148 Cr. | 118 | 247/84.3 | 32.8 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.36 Cr. | 1.76 | 4.33/1.76 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,222 Cr. | 387 | 479/192 | 87.4 | 24.3 | 0.17 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 35.4 Cr. | 47.6 | 92.2/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 43.1 Cr. | 29.4 | 30.5/17.0 | 103 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,631.82 Cr | 1,173.41 | 52.33 | 202.18 | 0.35% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Sep 2020 | Mar 2021 | Sep 2021 | Mar 2022 | Sep 2022 | Mar 2023 | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 22.36 | 48.33 | 43.15 | 50.93 | 44.27 | 75.40 | 119.26 | 102.11 | 64.92 | 21.80 |
| Expenses | 20.71 | 46.67 | 41.53 | 49.87 | 43.24 | 73.60 | 124.26 | 104.15 | 66.11 | 22.06 |
| Operating Profit | 1.65 | 1.66 | 1.62 | 1.06 | 1.03 | 1.80 | -5.00 | -2.04 | -1.19 | -0.26 |
| OPM % | 7.38% | 3.43% | 3.75% | 2.08% | 2.33% | 2.39% | -4.19% | -2.00% | -1.83% | -1.19% |
| Other Income | 0.02 | 0.46 | 0.47 | 1.15 | 0.60 | 0.19 | 7.01 | 4.32 | 3.07 | 2.45 |
| Interest | 1.62 | 1.86 | 1.45 | 1.63 | 1.04 | 1.15 | 0.66 | 0.73 | 0.85 | 1.10 |
| Depreciation | 0.01 | 0.02 | 0.06 | 0.06 | 0.05 | 0.22 | 0.43 | 0.21 | 0.41 | 0.54 |
| Profit before tax | 0.04 | 0.24 | 0.58 | 0.52 | 0.54 | 0.62 | 0.92 | 1.34 | 0.62 | 0.55 |
| Tax % | 25.00% | 33.33% | 24.14% | 30.77% | 31.48% | 14.52% | 31.52% | 33.58% | -11.29% | 69.09% |
| Net Profit | 0.03 | 0.16 | 0.43 | 0.36 | 0.37 | 0.54 | 0.63 | 0.90 | 0.68 | 0.17 |
| EPS in Rs | 0.04 | 0.21 | 0.57 | 0.48 | 0.49 | 0.72 | 0.83 | 1.19 | 0.90 | 0.23 |
Last Updated: May 31, 2025, 6:33 am
Below is a detailed analysis of the quarterly data for Chandra Bhagat Pharma Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Sales, as of Mar 2025, the value is 21.80 Cr.. The value appears to be declining and may need further review. It has decreased from 64.92 Cr. (Sep 2024) to 21.80 Cr., marking a decrease of 43.12 Cr..
- For Expenses, as of Mar 2025, the value is 22.06 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 66.11 Cr. (Sep 2024) to 22.06 Cr., marking a decrease of 44.05 Cr..
- For Operating Profit, as of Mar 2025, the value is -0.26 Cr.. The value appears strong and on an upward trend. It has increased from -1.19 Cr. (Sep 2024) to -0.26 Cr., marking an increase of 0.93 Cr..
- For OPM %, as of Mar 2025, the value is -1.19%. The value appears strong and on an upward trend. It has increased from -1.83% (Sep 2024) to -1.19%, marking an increase of 0.64%.
- For Other Income, as of Mar 2025, the value is 2.45 Cr.. The value appears to be declining and may need further review. It has decreased from 3.07 Cr. (Sep 2024) to 2.45 Cr., marking a decrease of 0.62 Cr..
- For Interest, as of Mar 2025, the value is 1.10 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.85 Cr. (Sep 2024) to 1.10 Cr., marking an increase of 0.25 Cr..
- For Depreciation, as of Mar 2025, the value is 0.54 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.41 Cr. (Sep 2024) to 0.54 Cr., marking an increase of 0.13 Cr..
- For Profit before tax, as of Mar 2025, the value is 0.55 Cr.. The value appears to be declining and may need further review. It has decreased from 0.62 Cr. (Sep 2024) to 0.55 Cr., marking a decrease of 0.07 Cr..
- For Tax %, as of Mar 2025, the value is 69.09%. The value appears to be increasing, which may not be favorable. It has increased from -11.29% (Sep 2024) to 69.09%, marking an increase of 80.38%.
- For Net Profit, as of Mar 2025, the value is 0.17 Cr.. The value appears to be declining and may need further review. It has decreased from 0.68 Cr. (Sep 2024) to 0.17 Cr., marking a decrease of 0.51 Cr..
- For EPS in Rs, as of Mar 2025, the value is 0.23. The value appears to be declining and may need further review. It has decreased from 0.90 (Sep 2024) to 0.23, marking a decrease of 0.67.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: October 15, 2025, 3:40 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 48.01 | 61.13 | 79.84 | 89.79 | 97.06 | 106.28 | 93.97 | 70.70 | 94.04 | 119.67 | 221.37 | 86.72 |
| Expenses | 46.18 | 58.13 | 76.42 | 85.41 | 92.47 | 101.69 | 90.85 | 67.02 | 91.20 | 116.33 | 228.41 | 88.14 |
| Operating Profit | 1.83 | 3.00 | 3.42 | 4.38 | 4.59 | 4.59 | 3.12 | 3.68 | 2.84 | 3.34 | -7.04 | -1.42 |
| OPM % | 3.81% | 4.91% | 4.28% | 4.88% | 4.73% | 4.32% | 3.32% | 5.21% | 3.02% | 2.79% | -3.18% | -1.64% |
| Other Income | 0.64 | 0.31 | 0.38 | 0.49 | 0.67 | 0.44 | 0.44 | 0.48 | 1.62 | 0.29 | 11.33 | 5.49 |
| Interest | 1.88 | 2.35 | 2.83 | 3.81 | 3.67 | 4.09 | 3.11 | 3.76 | 3.24 | 2.20 | 1.39 | 1.95 |
| Depreciation | 0.17 | 0.26 | 0.24 | 0.14 | 0.06 | 0.05 | 0.03 | 0.12 | 0.12 | 0.27 | 0.64 | 0.95 |
| Profit before tax | 0.42 | 0.70 | 0.73 | 0.92 | 1.53 | 0.89 | 0.42 | 0.28 | 1.10 | 1.16 | 2.26 | 1.17 |
| Tax % | 16.67% | 38.57% | 50.68% | 27.17% | 32.68% | 22.47% | 26.19% | 32.14% | 27.27% | 21.55% | 32.74% | 26.50% |
| Net Profit | 0.35 | 0.43 | 0.35 | 0.66 | 1.03 | 0.69 | 0.31 | 0.19 | 0.80 | 0.91 | 1.53 | 0.86 |
| EPS in Rs | 8.37 | 10.29 | 8.37 | 15.79 | 24.64 | 10.29 | 0.41 | 0.25 | 1.06 | 1.21 | 2.03 | 1.14 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 22.86% | -18.60% | 88.57% | 56.06% | -33.01% | -55.07% | -38.71% | 321.05% | 13.75% | 68.13% | -43.79% |
| Change in YoY Net Profit Growth (%) | 0.00% | -41.46% | 107.18% | -32.51% | -89.07% | -22.06% | 16.36% | 359.76% | -307.30% | 54.38% | -111.92% |
Chandra Bhagat Pharma Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 4% |
| 5 Years: | -2% |
| 3 Years: | -3% |
| TTM: | -61% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | 23% |
| 3 Years: | 2% |
| TTM: | -44% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 4% |
| 3 Years: | -23% |
| 1 Year: | -39% |
| Return on Equity | |
|---|---|
| 10 Years: | 4% |
| 5 Years: | 3% |
| 3 Years: | 4% |
| Last Year: | 3% |
Last Updated: September 5, 2025, 2:51 pm
Balance Sheet
Last Updated: December 4, 2025, 2:36 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 0.42 | 0.42 | 0.42 | 0.42 | 0.42 | 0.67 | 7.55 | 7.55 | 7.55 | 7.55 | 7.55 | 7.55 | 7.55 |
| Reserves | 5.55 | 5.98 | 6.33 | 6.99 | 8.03 | 13.78 | 18.14 | 18.33 | 19.13 | 19.93 | 21.46 | 22.42 | 22.87 |
| Borrowings | 18.58 | 27.50 | 27.83 | 22.08 | 21.75 | 31.22 | 29.93 | 27.07 | 21.11 | 18.94 | 16.43 | 20.86 | 21.11 |
| Other Liabilities | 7.07 | 8.39 | 9.91 | 26.40 | 27.86 | 37.19 | 19.12 | 18.83 | 24.68 | 14.16 | 56.37 | 50.70 | 36.67 |
| Total Liabilities | 31.62 | 42.29 | 44.49 | 55.89 | 58.06 | 82.86 | 74.74 | 71.78 | 72.47 | 60.58 | 101.81 | 101.53 | 88.20 |
| Fixed Assets | 1.02 | 0.87 | 0.69 | 0.55 | 0.51 | 0.46 | 0.44 | 0.42 | 0.47 | 0.73 | 2.52 | 2.62 | 2.04 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 4.64 | 1.05 | 4.03 | 0.75 | 0.00 | 0.22 | 0.11 | 0.13 | 0.14 | 1.19 |
| Other Assets | 30.60 | 41.42 | 43.80 | 50.70 | 56.50 | 78.37 | 73.55 | 71.36 | 71.78 | 59.74 | 99.16 | 98.77 | 84.97 |
| Total Assets | 31.62 | 42.29 | 44.49 | 55.89 | 58.06 | 82.86 | 74.74 | 71.78 | 72.47 | 60.58 | 101.81 | 101.53 | 88.20 |
Below is a detailed analysis of the balance sheet data for Chandra Bhagat Pharma Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 7.55 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 7.55 Cr..
- For Reserves, as of Sep 2025, the value is 22.87 Cr.. The value appears strong and on an upward trend. It has increased from 22.42 Cr. (Mar 2025) to 22.87 Cr., marking an increase of 0.45 Cr..
- For Borrowings, as of Sep 2025, the value is 21.11 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 20.86 Cr. (Mar 2025) to 21.11 Cr., marking an increase of 0.25 Cr..
- For Other Liabilities, as of Sep 2025, the value is 36.67 Cr.. The value appears to be improving (decreasing). It has decreased from 50.70 Cr. (Mar 2025) to 36.67 Cr., marking a decrease of 14.03 Cr..
- For Total Liabilities, as of Sep 2025, the value is 88.20 Cr.. The value appears to be improving (decreasing). It has decreased from 101.53 Cr. (Mar 2025) to 88.20 Cr., marking a decrease of 13.33 Cr..
- For Fixed Assets, as of Sep 2025, the value is 2.04 Cr.. The value appears to be declining and may need further review. It has decreased from 2.62 Cr. (Mar 2025) to 2.04 Cr., marking a decrease of 0.58 Cr..
- For CWIP, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Investments, as of Sep 2025, the value is 1.19 Cr.. The value appears strong and on an upward trend. It has increased from 0.14 Cr. (Mar 2025) to 1.19 Cr., marking an increase of 1.05 Cr..
- For Other Assets, as of Sep 2025, the value is 84.97 Cr.. The value appears to be declining and may need further review. It has decreased from 98.77 Cr. (Mar 2025) to 84.97 Cr., marking a decrease of 13.80 Cr..
- For Total Assets, as of Sep 2025, the value is 88.20 Cr.. The value appears to be declining and may need further review. It has decreased from 101.53 Cr. (Mar 2025) to 88.20 Cr., marking a decrease of 13.33 Cr..
Notably, the Reserves (22.87 Cr.) exceed the Borrowings (21.11 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -16.75 | -24.50 | -24.41 | -17.70 | -17.16 | -26.63 | -26.81 | -23.39 | -18.27 | -15.60 | -23.47 | -22.28 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 65.15 | 70.99 | 66.15 | 79.92 | 67.16 | 90.32 | 54.50 | 79.61 | 58.22 | 24.98 | 65.05 | 151.31 |
| Inventory Days | 161.44 | 176.71 | 122.83 | 132.66 | 144.60 | 173.53 | 186.75 | 214.70 | 153.25 | 99.59 | 15.23 | 3.44 |
| Days Payable | 53.01 | 43.18 | 32.81 | 80.69 | 68.58 | 117.37 | 53.13 | 78.51 | 11.98 | 10.62 | 23.21 | 44.58 |
| Cash Conversion Cycle | 173.59 | 204.52 | 156.17 | 131.89 | 143.18 | 146.48 | 188.12 | 215.80 | 199.49 | 113.95 | 57.06 | 110.17 |
| Working Capital Days | 148.78 | 166.47 | 133.63 | 124.96 | 138.50 | 83.39 | 147.60 | 177.18 | 103.94 | 75.00 | 35.89 | 115.28 |
| ROCE % | 11.68% | 10.44% | 10.40% | 14.77% | 17.42% | 13.13% | 6.97% | 7.44% | 8.62% | 7.13% | 7.95% | 6.00% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 1.14 | 2.03 | 1.20 | 1.06 | 0.25 |
| Diluted EPS (Rs.) | 1.14 | 2.03 | 1.20 | 1.06 | 0.25 |
| Cash EPS (Rs.) | 2.40 | 2.88 | 1.55 | 1.22 | 0.29 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 39.72 | 38.45 | 36.42 | 35.35 | 34.30 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 39.72 | 38.45 | 36.42 | 35.35 | 34.30 |
| Revenue From Operations / Share (Rs.) | 114.93 | 293.40 | 158.61 | 124.68 | 93.70 |
| PBDIT / Share (Rs.) | 5.39 | 5.69 | 4.79 | 5.69 | 1.05 |
| PBIT / Share (Rs.) | 4.13 | 4.84 | 4.44 | 5.53 | 1.01 |
| PBT / Share (Rs.) | 1.54 | 3.00 | 1.54 | 1.45 | 0.36 |
| Net Profit / Share (Rs.) | 1.14 | 2.03 | 1.20 | 1.05 | 0.25 |
| PBDIT Margin (%) | 4.68 | 1.93 | 3.01 | 4.56 | 1.12 |
| PBIT Margin (%) | 3.58 | 1.64 | 2.79 | 4.43 | 1.07 |
| PBT Margin (%) | 1.34 | 1.02 | 0.97 | 1.16 | 0.39 |
| Net Profit Margin (%) | 0.98 | 0.69 | 0.75 | 0.84 | 0.26 |
| Return on Networth / Equity (%) | 2.86 | 5.27 | 3.29 | 2.98 | 0.73 |
| Return on Capital Employeed (%) | 9.64 | 11.86 | 9.95 | 12.12 | 1.95 |
| Return On Assets (%) | 0.84 | 1.50 | 1.49 | 1.09 | 0.26 |
| Long Term Debt / Equity (X) | 0.07 | 0.04 | 0.14 | 0.20 | 0.36 |
| Total Debt / Equity (X) | 0.69 | 0.56 | 0.68 | 0.74 | 0.96 |
| Asset Turnover Ratio (%) | 0.85 | 2.73 | 1.80 | 1.30 | 0.96 |
| Current Ratio (X) | 1.41 | 1.38 | 2.19 | 1.86 | 2.13 |
| Quick Ratio (X) | 1.40 | 1.26 | 1.11 | 0.96 | 1.06 |
| Inventory Turnover Ratio (X) | 18.51 | 1.54 | 0.53 | 0.07 | 0.23 |
| Interest Coverage Ratio (X) | 2.09 | 3.09 | 1.65 | 1.40 | 1.65 |
| Interest Coverage Ratio (Post Tax) (X) | 1.44 | 2.10 | 1.41 | 1.26 | 1.39 |
| Enterprise Value (Cr.) | 59.68 | 83.14 | 85.69 | 99.92 | 52.54 |
| EV / Net Operating Revenue (X) | 0.68 | 0.37 | 0.71 | 1.06 | 0.74 |
| EV / EBITDA (X) | 14.68 | 19.38 | 23.71 | 23.26 | 66.02 |
| MarketCap / Net Operating Revenue (X) | 0.45 | 0.32 | 0.61 | 0.91 | 0.42 |
| Price / BV (X) | 1.32 | 2.47 | 2.66 | 3.22 | 1.15 |
| Price / Net Operating Revenue (X) | 0.45 | 0.32 | 0.61 | 0.91 | 0.42 |
| EarningsYield | 0.02 | 0.02 | 0.01 | 0.01 | 0.01 |
After reviewing the key financial ratios for Chandra Bhagat Pharma Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 1.14. This value is below the healthy minimum of 5. It has decreased from 2.03 (Mar 24) to 1.14, marking a decrease of 0.89.
- For Diluted EPS (Rs.), as of Mar 25, the value is 1.14. This value is below the healthy minimum of 5. It has decreased from 2.03 (Mar 24) to 1.14, marking a decrease of 0.89.
- For Cash EPS (Rs.), as of Mar 25, the value is 2.40. This value is below the healthy minimum of 3. It has decreased from 2.88 (Mar 24) to 2.40, marking a decrease of 0.48.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 39.72. It has increased from 38.45 (Mar 24) to 39.72, marking an increase of 1.27.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 39.72. It has increased from 38.45 (Mar 24) to 39.72, marking an increase of 1.27.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 114.93. It has decreased from 293.40 (Mar 24) to 114.93, marking a decrease of 178.47.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 5.39. This value is within the healthy range. It has decreased from 5.69 (Mar 24) to 5.39, marking a decrease of 0.30.
- For PBIT / Share (Rs.), as of Mar 25, the value is 4.13. This value is within the healthy range. It has decreased from 4.84 (Mar 24) to 4.13, marking a decrease of 0.71.
- For PBT / Share (Rs.), as of Mar 25, the value is 1.54. This value is within the healthy range. It has decreased from 3.00 (Mar 24) to 1.54, marking a decrease of 1.46.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 1.14. This value is below the healthy minimum of 2. It has decreased from 2.03 (Mar 24) to 1.14, marking a decrease of 0.89.
- For PBDIT Margin (%), as of Mar 25, the value is 4.68. This value is below the healthy minimum of 10. It has increased from 1.93 (Mar 24) to 4.68, marking an increase of 2.75.
- For PBIT Margin (%), as of Mar 25, the value is 3.58. This value is below the healthy minimum of 10. It has increased from 1.64 (Mar 24) to 3.58, marking an increase of 1.94.
- For PBT Margin (%), as of Mar 25, the value is 1.34. This value is below the healthy minimum of 10. It has increased from 1.02 (Mar 24) to 1.34, marking an increase of 0.32.
- For Net Profit Margin (%), as of Mar 25, the value is 0.98. This value is below the healthy minimum of 5. It has increased from 0.69 (Mar 24) to 0.98, marking an increase of 0.29.
- For Return on Networth / Equity (%), as of Mar 25, the value is 2.86. This value is below the healthy minimum of 15. It has decreased from 5.27 (Mar 24) to 2.86, marking a decrease of 2.41.
- For Return on Capital Employeed (%), as of Mar 25, the value is 9.64. This value is below the healthy minimum of 10. It has decreased from 11.86 (Mar 24) to 9.64, marking a decrease of 2.22.
- For Return On Assets (%), as of Mar 25, the value is 0.84. This value is below the healthy minimum of 5. It has decreased from 1.50 (Mar 24) to 0.84, marking a decrease of 0.66.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.07. This value is below the healthy minimum of 0.2. It has increased from 0.04 (Mar 24) to 0.07, marking an increase of 0.03.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.69. This value is within the healthy range. It has increased from 0.56 (Mar 24) to 0.69, marking an increase of 0.13.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.85. It has decreased from 2.73 (Mar 24) to 0.85, marking a decrease of 1.88.
- For Current Ratio (X), as of Mar 25, the value is 1.41. This value is below the healthy minimum of 1.5. It has increased from 1.38 (Mar 24) to 1.41, marking an increase of 0.03.
- For Quick Ratio (X), as of Mar 25, the value is 1.40. This value is within the healthy range. It has increased from 1.26 (Mar 24) to 1.40, marking an increase of 0.14.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 18.51. This value exceeds the healthy maximum of 8. It has increased from 1.54 (Mar 24) to 18.51, marking an increase of 16.97.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 2.09. This value is below the healthy minimum of 3. It has decreased from 3.09 (Mar 24) to 2.09, marking a decrease of 1.00.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 1.44. This value is below the healthy minimum of 3. It has decreased from 2.10 (Mar 24) to 1.44, marking a decrease of 0.66.
- For Enterprise Value (Cr.), as of Mar 25, the value is 59.68. It has decreased from 83.14 (Mar 24) to 59.68, marking a decrease of 23.46.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 0.68. This value is below the healthy minimum of 1. It has increased from 0.37 (Mar 24) to 0.68, marking an increase of 0.31.
- For EV / EBITDA (X), as of Mar 25, the value is 14.68. This value is within the healthy range. It has decreased from 19.38 (Mar 24) to 14.68, marking a decrease of 4.70.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.45. This value is below the healthy minimum of 1. It has increased from 0.32 (Mar 24) to 0.45, marking an increase of 0.13.
- For Price / BV (X), as of Mar 25, the value is 1.32. This value is within the healthy range. It has decreased from 2.47 (Mar 24) to 1.32, marking a decrease of 1.15.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.45. This value is below the healthy minimum of 1. It has increased from 0.32 (Mar 24) to 0.45, marking an increase of 0.13.
- For EarningsYield, as of Mar 25, the value is 0.02. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.02.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Chandra Bhagat Pharma Ltd:
- Net Profit Margin: 0.98%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 9.64% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 2.86% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 1.44
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.4
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 42.6 (Industry average Stock P/E: 52.33)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.69
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 0.98%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | 323-F Bhagat Bhuvan, Mumbai Maharashtra 400019 | compliancecbc@gmail.com http://www.cbcpharma.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Hemant Chandravadan Bhagat | Chairman & Managing Director |
| Mr. Pranav Hemant Bhagat | Whole Time Director |
| Mrs. Prachi Pranav Bhagat | Director & CFO |
| Mr. Ravindra Gajanan Awati | Independent Director |
| Ms. Abha Praveen Doshi | Independent Director |
FAQ
What is the intrinsic value of Chandra Bhagat Pharma Ltd?
Chandra Bhagat Pharma Ltd's intrinsic value (as of 05 December 2025) is 33.76 which is 3.54% lower the current market price of 35.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 26.4 Cr. market cap, FY2025-2026 high/low of 80.0/35.0, reserves of ₹22.87 Cr, and liabilities of 88.20 Cr.
What is the Market Cap of Chandra Bhagat Pharma Ltd?
The Market Cap of Chandra Bhagat Pharma Ltd is 26.4 Cr..
What is the current Stock Price of Chandra Bhagat Pharma Ltd as on 05 December 2025?
The current stock price of Chandra Bhagat Pharma Ltd as on 05 December 2025 is 35.0.
What is the High / Low of Chandra Bhagat Pharma Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Chandra Bhagat Pharma Ltd stocks is 80.0/35.0.
What is the Stock P/E of Chandra Bhagat Pharma Ltd?
The Stock P/E of Chandra Bhagat Pharma Ltd is 42.6.
What is the Book Value of Chandra Bhagat Pharma Ltd?
The Book Value of Chandra Bhagat Pharma Ltd is 40.3.
What is the Dividend Yield of Chandra Bhagat Pharma Ltd?
The Dividend Yield of Chandra Bhagat Pharma Ltd is 0.00 %.
What is the ROCE of Chandra Bhagat Pharma Ltd?
The ROCE of Chandra Bhagat Pharma Ltd is 6.00 %.
What is the ROE of Chandra Bhagat Pharma Ltd?
The ROE of Chandra Bhagat Pharma Ltd is 2.41 %.
What is the Face Value of Chandra Bhagat Pharma Ltd?
The Face Value of Chandra Bhagat Pharma Ltd is 10.0.